294,127 Shares in Tempus AI, Inc. $TEM Acquired by Casdin Capital LLC

Casdin Capital LLC purchased a new position in Tempus AI, Inc. (NASDAQ:TEM) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 294,127 shares of the company’s stock, valued at approximately $23,739,000. Tempus AI makes up approximately 2.0% of Casdin Capital LLC’s portfolio, making the stock its 11th largest position.

A number of other hedge funds have also recently added to or reduced their stakes in TEM. Renaissance Capital LLC lifted its holdings in shares of Tempus AI by 26.9% in the 3rd quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock worth $6,793,000 after purchasing an additional 17,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Tempus AI by 1,459.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after purchasing an additional 94,783 shares during the period. Hussman Strategic Advisors Inc. bought a new stake in Tempus AI during the 3rd quarter valued at $1,695,000. Krane Funds Advisors LLC increased its stake in Tempus AI by 218.2% during the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after purchasing an additional 19,358 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after buying an additional 1,706,837 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. HC Wainwright raised their price objective on shares of Tempus AI from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Canaccord Genuity Group decreased their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, December 22nd. JPMorgan Chase & Co. lowered their target price on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a research report on Wednesday, February 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $78.62.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $49.98 on Friday. The company has a current ratio of 3.13, a quick ratio of 3.00 and a debt-to-equity ratio of 2.52. The stock has a market cap of $8.93 billion, a PE ratio of -35.45 and a beta of 5.29. The stock’s fifty day simple moving average is $59.20 and its two-hundred day simple moving average is $71.70. Tempus AI, Inc. has a 1-year low of $36.22 and a 1-year high of $104.32.

Insider Buying and Selling

In related news, CFO James William Rogers sold 10,084 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $595,460.20. Following the transaction, the chief financial officer directly owned 101,166 shares of the company’s stock, valued at $5,973,852.30. This trade represents a 9.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Eric P. Lefkofsky sold 13,587 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $802,312.35. Following the transaction, the chief executive officer owned 1,989,626 shares in the company, valued at approximately $117,487,415.30. This trade represents a 0.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 570,143 shares of company stock valued at $35,595,055 over the last 90 days. 26.27% of the stock is currently owned by company insiders.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.